key: cord-0993526-3a3imwzk
authors: Yesilkaya, Umit Haluk; Sen, Meltem; Karamustafalioglu, Nesrin
title: New variants and new symptoms in COVID-19: First episode psychosis and Cotard's Syndrome two months after infection with the B.1.1.7 variant of coronavirus
date: 2021-06-16
journal: Schizophr Res
DOI: 10.1016/j.schres.2021.06.001
sha: 7c7b6c56c62f7b082e235e4325e5c0a80aefb095
doc_id: 993526
cord_uid: 3a3imwzk

nan

During the course of coronavirus disease-2019 pandemic, many neuropsychiatric manifestations of the disease have been observed while the precise pathophysiology remains unknown. (Sen et al., 2021; Yesilkaya et al., 2021) New variants of coronavirus such as the 501.V2 and B.1.1.7 have emerged and obscurities in pathogenesis have increased even further with these variants. Here, we describe a patient with long-term effects of COVID-19, manifesting first episode psychosis accompanied by Cotard's Syndrome (CS) after infection with the B.1.1.7 variant of SARS-CoV-2.

A 41-year-old female primary school teacher with no adverse medical history was admitted to the emergency department with symptoms of loss of smell, myalgia and sore throat. Upon confirmation of COVID-19 infection by a positive RT-PCR test result for the B.1.1.7 variant of coronavirus, the national COVID-19 treatment protocol with favipravir and hydroxychloroquine was started. The patient's symptoms improved gradually and a negative RT-PCR result was confirmed on the tenth day. The loss of smell, however, remained. Two months after the completion of treatment for COVID-19, the patient started to have thoughts of being annihilated by viral occupation of her body and of her nervous system getting decomposed. The patient's family brought her to the psychiatric emergency department with complaints of inability to continue with the teaching job at her primary school, staying in her room for hours without eating or talking and alluding to her death and suicide plans.

The patient was found to have strong suicidal ideations, referential thoughts, belief of being physically dead and her children being in danger of obliteration by COVID-19. As the patient believed that she was dead, she wanted to prove this to her family by committing suicide with the J o u r n a l P r e -p r o o f Journal Pre-proof notion that that nothing would ever change afterwards. Clinical evaluation of the mental state of the patient suggested that cooperation and orientation were intact while speech output and speed as well as psychomotor activity were decreased. The patient was anxious, while her mood was dysphoric. Nihilistic, persecutory and referential delusions with no insight were recorded. The Positive and Negative Syndrome Scale (PANSS) score was 109. Physical and neurological examinations, blood tests and magnetic resonance imaging (MRI) revealed no significant findings. Upon hospitalization, despite her treatment with olanzapine 20 mg/day orally with an initial diagnosis of first episode psychosis and CS, her delusions and suicidal ideation persisted.

Therefore, electroconvulsive therapy (ECT) was planned. Upon receiving 8 sessions of ECT along with olanzapine administration, her psychiatric symptoms and suicidal ideation ameliorated. The patients' PANSS score regressed to 54; however, her loss of smell continued.

The patient was discharged from the hospital with olanzapine 20mg/day orally and she is currently being followed-up in our outpatient clinic.

To the best of our knowledge, this is the first report of a patient who developed CS and psychotic symptoms associated with COVID-19 following infection with a new variant of coronavirus.

CS is a rare self-perceptual anomaly with the presentation of nihilistic delusions. Patients often claim that their body is physically dead and complain of a feeling of nothingness(Young et al.,

Schizophrenia and monothematic delusions

Two cases of late-onset anti-NMDAr auto-immune encephalitis after herpes simplex virus 1 encephalitis

Cotard syndrome in neurological and psychiatric patients

Cotard syndrome in anti-NMDAR encephalitis: two patients and insights from molecular imaging

SARS-CoV-2-associated first episode of acute mania with psychotic features